GSK plc (LSE: GSK)
Health Care · Pharmaceuticals · GB
£19.06
+0.79% today · +29.7% 1Y
GSK plc (LSE: GSK) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $104.10B and employs 66,841 people.
Over the last twelve months the share price has gained 29.7%, trading between 12.89 and 22.82.
Tweenvest scores GSK plc across four factors: quality 81/100, value 43/100, growth 29/100, dividend 62/100. Its strongest factor is quality.
GSK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $104.10B
- Revenue (TTM)
- $44.05B
- P/E
- 16.17
- EPS
- 1.18
- Dividend yield
- 3.81%
- Beta (5Y)
- 0.29
- 52-week high
- £22.82
- 52-week low
- £12.89
- Avg volume (3M)
- —
- Shares outstanding
- 4.01B
- Employees
- 66,841
- Next earnings
- —
About GSK plc
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.
- ISIN
- GB00BN7SWP63
- Founded
- 1715
- Listed since
- Jul 1, 1988
- Exchange
- London Stock Exchange
- Currency
- GBP
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.